NCT02057172View on ClinicalTrials.gov

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

254

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Type 2 Diabetes
Interventions
DRUG

HM11260C

HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)

DRUG

liraglutide

Liraglutide is a GLP-1 agonist.

DRUG

Placebo

Placebo

Trial Locations (1)

Unknown

Hanmi pharmaceutical, CA

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02057172 - Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes | Biotech Hunter | Biotech Hunter